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Thin basement membrane disease (TBMD) typically presents
with persistent microscopic hematuria, and is usually defined
as a glomerular basement membrane (GBM) thickness
o250nm. Previous studies showed that neither the degree of
thinning nor the extent of the abnormality correlate with the
patient’s clinical presentation or prognosis. To further define
this, we enrolled a study group of 41 patients with isolated
microscopic hematuria and a normal renal biopsy, except those
with a GBM thickness of 250–320nm, and compared them with
33 patients with traditional TBMD. We found no difference in
baseline demographic or clinical parameter between the
groups. After follow-up averaging 110 months, there was no
significant difference in the risk of detectable or overt
proteinuria, hypertension, or impaired renal function between
the groups. By the end of the study, only five patients from the
study group and four from the TBMD group had no outcome
event. By Cox regression analysis, independent predictors
of overt proteinuria were male gender, age at biopsy, baseline
renal function, proteinuria, and hypertension. Age at biopsy
was the only independent predictor for hypertension, and
baseline proteinuria was the only independent predictor for
impaired renal function. GBM thickness did not predict any
outcome event. Hence, lifelong follow-up is advised, as the
clinical features and prognosis of these patients with persistent
microscopic hematuria and marginally thin GBM are similar
to traditional TBMD.
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Thin basement membrane disease (TBMD), also called
benign recurrent hematuria, is characterized by persistent
microscopic hematuria and diffuse thinning of the glomer-
ular basement membrane (GBM) under electron micro-
scopy.1,2 Both direct and indirect approaches suggest that
TBMD occurs in 41% of the population, which makes it one
of the most common conditions affecting the kidney after
infections, hypertension, and stones.2–5
Traditionally, TBMD is believed to be benign, with
little risk of hypertension or progression to chronic kidney
disease.6 However, more recent studies showed that the
condition may not be universally benign, especially in
adults.2,7–9 A median of 50% adults with TBMD had some
degree of proteinuria, 16% had proteinuria 4500 mg/day,
and 17% had hypertension, and up to 29% had renal
impairment.2 In addition, van Paassen et al.7 found that
B15% of TBMD has substantial proteinuria, which is
associated in the majority of cases with the lesions of focal
segmental glomerulosclerosis, particularly those in late
middle age. Furthermore, Nieuwhof et al.9 reported that
renal function may decline in a considerable proportion of
patients with TBMD during prolonged follow-up, and blood
pressure may increase in many affected individuals, suggest-
ing that the long-term prognosis may be less favorable than
previously believed. More recently, Voskarides et al.10 identi-
fied specific mutations associated with the development of
proteinuria, renal failure, and segmental glomerulosclerosis
in patients with morphological TBMD.
The diagnosis of TBMD is morphological and somewhat
arbitrary. Although GBM thickness is greater in normal males
than females, whereas GBM is thinner in children than
adults,11 most authors agree that an average GBM thickness
of o250 mm by the orthogonal intercept method (around
two standard deviations below the mean of normal
adult values) should be considered abnormal.11,12 However,
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previous studies showed that neither the degree of thinning
nor the extent of the abnormality correlate with the patient’s
clinical presentation or prognosis. In fact, some patients
present with persistent microscopic hematuria and have no
renal pathology identified except a GBM thickness of
250–320 mm (that is, average value of normal female); their
clinical behavior remains unknown.
RESULTS
Demographic and clinical features
The average duration from the time of presentation to renal
biopsy was 42.5±44.8 months. The baseline demographic
and clinical data of the two groups are summarized and
compared in Table 1. In short, there was no significant
difference in any of the baseline parameters between groups.
None of the patients had hearing impairment clinically.
However, 13 patients from the study group and 9 from the
TBMD group were randomly selected and referred for pure-
tone audiometry. Five from the study group and one from
the TBMD group were found to have sensorineural hearing
loss (Fisher’s exact test; P¼ 0.3).
Immunofluorescence
Immunofluorescence for a-3 and a-5 chains of type IV
collagen was performed in 27 patients of the study group and
26 of the TBMD group. One patient of the TBMD group
showed absence of a-5 chains of type IV collagen; one patient
from the study group (who also had sensorineural hearing
loss) and four from the TBMD group showed fragmented
staining, suggestive of heterozygous for mutations of Alport’s
syndrome.
Clinical outcome
The average duration of follow-up was 109.8±74.2 months.
At the end of the study period, 33 patients of the study group
had detectable proteinuria, 17 had overt proteinuria, 17 had
hypertension, and 4 had impaired renal function. For the
TBMD group, 29 patients had detectable proteinuria, 15 had
overt proteinuria, 10 had hypertension, and 1 had impaired
renal function. The Kaplan–Meier plots of event-free survival
of the two groups are shown in Figure 1. In short, there was
no significant difference in the risk of any outcome measure
between the groups. By the end of the study period, only
five patients from the study group and four from the
TBMD group had no outcome event (that is, remained free
of any detectable proteinuria, hypertension, or impaired renal
function). Of the six patients who had absent or fragmented
GBM staining for a-5 chains of type IV collagen, five
developed detectable proteinuria, one had hypertension, one
had overt proteinuria, and none had impaired renal function
at the end of the study period. The result remained similar
when patients with absent or fragmented GBM immuno-
fluorescence staining were excluded from the analysis (details
not shown).
Effect of basement membrane thickness
We compared the GBM thickness between patients who did
and did not develop detectable proteinuria, overt proteinuria,
hypertension, or impaired renal function (Figure 2). In short,
no significant difference was found. There was also no
significant difference in the intraindividual variation of GBM
thickness between patients who did and did not develop
clinical events (details not shown).
The result of Cox regression analysis on the predictors
of development of outcome events is summarized in
Table 2. From the Cox models, independent predictors for
the development of overt proteinuria were male sex, age at
biopsy, baseline renal function, proteinuria, and hyperten-
sion. On the other hand, age at biopsy was the only
independent predictor for the development of hypertension,
whereas baseline proteinuria was the only independent
Table 1 | Comparison of clinical presentation between groups
Group Study group TBMD group
Total no. of patients 41 33
Sex (M:F) 10:31 3:30
Age (years) 36.7±10.3 (15–55) 37.1±7.9
Body weight (kg) 60.0±11.8 (38–80) 58.6±8.0
Blood pressure (mmHg)
Systolic 132.7±17.1 129.8±17.1
Diastolic 77.9±14.5 75.6±10.8
Clinical features (no. of cases (%))
Microscopic hematuria 41 (100%) 33 (100%)
Macroscopic hematuria 1 (2.4%) 2 (6.1%)
Detectable proteinuria 24 (58.5%) 22 (66.7%)
Hypertension 15 (36.6%) 6 (18.2%)
Proteinuria X1 g/daya 6 (14.6%) 8 (24.2%)
Impaired renal functiona 2 (4.9%) 0
Family history (no. of cases (%))
Hematuria 2 (4.9%) 2 (6.1%)
Renal failure 0 2 (6.1%)
Hearing problem 1 (2.4%) 0
Glucose intolerance (no. of cases (%))
Diabetesb 1 (2.4%) 2 (6.1%)
Impaired fasting glucose 4 (9.8%) 2 (6.1%)
Biochemical parameters
Serum creatinine (mmol/l) 76.1±29.0 71.4±13.5
Estimated GFR (ml/min per
1.73m2)
92.5±25.7 89.6±17.3
Proteinuria (g/day) 0.49±0.74 0.64±0.70
GBM thickness (nm; mean±s.d. (range))
Mean thicknessc 275.8±18.3
(251–325)
224.9±21.9
(172–249)
ISDd 63.4±11.8 (38–92) 59.7±15.2 (33–87)
Abbreviations: GFR, glomerular filtration rate; GN, glomerulonephritis; ISD,
intraindividual standard deviation of basement membrane thickness; s.d., standard
deviation; TBMD, thin basement membrane disease.
aSome patients were labeled as having proteinuria over 1 g/day or impaired renal
function by the referring physician, but they actually did not have such a problem
when being assessed by us or around the time of kidney biopsy.
bAll required diet control only.
cPo0.0001 between the groups.
dP=0.26 between the groups.
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predictor for the development of impaired renal function
during follow-up. GBM thickness and intraindividual varia-
tion in GBM thickness did not appear in the final Cox model
of any of the outcome events. The result remained similar
when patients with absent or fragmented GBM immuno-
fluorescence staining were excluded from the analysis
(details not shown).
DISCUSSION
In the present study, we found that patients with persistent
microscopic hematuria and a marginally thin GBM
(250–320 nm) had identical clinical presentation and prog-
nosis as compared with those with definite TBMD (GBM
thickness below 250 nm). Our result suggests that the current
cutoff of GBM thickness for the diagnosis of TBMD may be
too stringent, and a substantial proportion of patients who
behave clinically as having TBMD (in terms of presentation
and prognosis) would be missed by the current criteria.
It is important to realize that determination of GBM
thickness is highly method dependent. Very different results
on the same specimen could be obtained by using orthogonal
intercept/mean harmonic thickness methods, as compared
with direct measurement/arithmetic mean methods.13 In
general, the former method, which was used in our study,
yields a higher GBM thickness as compared with the latter.
Nonetheless, even after allowing for the method of measuring
GBM, the prevalence of TBMD appears in our population to
be much lower than previous reports. TBMD was reported to
occur in 5–11% of the general population.14,15 In this study,
the prevalence of TBMD in the study of kidney biopsies
was 1%, whereas it was 1–2% in the study by Haas,16 and up
to 5% in another report by Cosio et al.17 We are not sure
whether the difference in prevalence was secondary to a
variation in renal biopsy policy or a genuine difference in
disease occurrence. In our previous study of 7828 asympto-
matic pregnant women,18 microscopic hematuria was present
in 2.6% of the participants, but hematuria resolved
spontaneously in most of the subjects. In this study, no case
of TBMD was identified.18 Although Sue et al.6 reported that
TBMD was present in 8% of Chinese patients who had
kidney biopsy, most of the patients in this series had other
coexisting glomerular diseases.
In this study, we found that the majority of our patients
had detectable proteinuria with extended follow-up, whereas
a considerable proportion developed overt proteinuria,
hypertension, or impaired renal function. The incidence of
clinical event observed in our patients is similar to previous
reports.2,7–10 In fact, the incidence of clinical event in the
present study is very much similar to our previous reports
on early IgA nephropathy with isolated microscopic hema-
turia and minimal proteinuria.19,20 Although clinical event
was frequent, our findings actually support the usual
recommendation that patients with isolated microscopic
hematuria could be regularly followed up without renal
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Figure 1 |Kaplan–Meier plot of event-free survival. (a) Any detectable proteinuria; (b) proteinuria X1 g/day; (c) hypertension; and (d)
impaired renal function. Data were compared using the log-rank test. TBMD, thin basement membrane disease.
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biopsy,21 because both of the two most common diagnoses
(that is, TBMD and IgA nephropathy) have no specific
treatment and a similar prognosis.
There are several unexpected observations in our study.
First, despite repeated direct questioning and careful
documentation, the percentage of patients, especially in the
TBMD group, with a history of macroscopic hematuria
or a family history of hematuria was very low (see Table 1).
The reason of this observation is unknown, although it adds
weight to the argument that most of these patients did not
have heterozygous Alport’s syndrome. In addition, as obesity
is associated with glomerular hyperfiltration and proteinuria,
it is somewhat surprising that body weight correlated
inversely with the risk of developing detectable proteinuria.
However, it should be noted that none of the patients in this
study had a body mass index 430, and only two had a body
mass index 427.
There are a few shortcomings of our study. First, the study
was retrospective and the sample size was small. As a result,
there could have been selection bias for renal biopsy, and we
actually did not have sufficient statistical power to perform
extensive multivariate analysis. Second, we did not perform
genetic study for our patients to confirm a mutation in the
type IV collagen gene, and it remains unknown whether
those patients with persistent microscopic hematuria and
marginally thin GBM had the same mutation as those with
TBMD. Similarly, we did not perform pure-tone audiometry
or other hearing test for all patients, and there could have
been selection bias in our reported incidence of hearing
problem. Although we attempted to determine the pre-
valence of heterozygous Alport’s syndrome in our study
population by immunofluorescence study, the test is not
100% sensitive, and immunofluorescence study was not
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Figure 2 |GBM thickness with and without events. Comparison of glomerular basement membrane (GBM) thickness between patients
with and without (a) detectable proteinuria; (b) overt proteinuria; (c) hypertension; and (d) impaired renal function. Whisker box plot with
boxes indicates median and 25 and 75 percentiles; whisker caps indicate 5 and 95 percentiles; and closed circles indicate outliers. Data were
compared using Student’s t-test.
Table 2 | Cox proportional hazards models
Variable AHR 95% CI P-value
Detectable proteinuria
Body weight (m 1 kg) 0.917 0.846–0.994 P=0.035
Overt proteinuria
Sexa 4.413 1.064–18.304 P=0.041
Age at biopsy (m 1 year) 1.116 1.026–1.215 P=0.010
Baseline GFR (m 1ml/min per 1.73m2) 1.029 1.001–1.059 P=0.047
Baseline proteinuria (m 0.1 g/day) 1.794 1.342–2.412 Po0.0001
Baseline hypertensionb 5.785 1.847–18.118 P=0.003
Hypertension
Age at biopsy (m 1 year) 1.118 1.001–1.249 P=0.049
Impaired renal function
Baseline proteinuria (m 0.1 g/day) 1.0386 1.003–1.075 P=0.033
Abbreviations: AHR, adjusted hazard ratio; CI, confidence interval; GFR, glomerular
filtration rate.
aMale (as compared with female).
bYes (as compared with no).
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possible in 21 patients of our study because of the limited
tissue availability. On the basis of our result, however, the
prevalence of heterozygous Alport’s syndrome was low in our
patient population with classical TBMD or borderline GBM
thickness.
We did not screen for glucose intolerance or insulin
resistance, which could be an important confounding factor
that affects GBM thickness. Traditionally, diffuse thickening
of GBM is considered a feature of diabetic nephropathy.
Recent evidence, however, suggests that isolated diffuse
thickening of GBM could be a manifestation of insulin
resistance and prediabetic state.22 As insulin resistance and
occult diabetes are common, it was possible that our patients
with marginally thin GBM actually had ordinary TBMD
together with occult diabetes or insulin resistance, which
conceivably increase the GBM thickness to a nondiagnostic
level. In addition, high fructose intake23 and copper
deficiency in the diet24 were found to increase the thickness
of GBM in rat models. There are, however, no data on this
topic in humans.
In summary, patients with persistent microscopic hema-
turia and a marginally thin GBM (250–320 nm) had sub-
stantial risk of developing overt proteinuria, hypertension, or
impaired renal function with prolonged follow-up. The
clinical feature and prognosis of these patients are similar
to that of traditional TBMD. Lifelong follow-up with
monitoring of blood pressure and renal function is advisable.
PATIENTS AND METHODS
Patient selection
From 1984 to 2006, there were 3991 renal biopsies performed
in our center. In our center, electron microscopy and
morphometric study of GBM thickness was performed in
all renal biopsy specimens for patients with unexplained
hematuria. We identified 41 patients (1.03%) who presented
with isolated microscopic hematuria, with renal biopsy
showing no specific renal pathology except a GBM thickness
of 250–320 nm (the study group). During the same period,
we identified another 40 patients (1.0%) with definite
TBMD, as defined by the presence of a GBM o250 nm and
having a unimodal distribution, using the orthogonal
intercept method by morphometric study of electron
microscopy. Seven were excluded from further analysis
because of coexisting glomerular diseases (minimal change
nephropathy, four cases; membranous nephropathy, IgA
nephropathy, and hypertensive nephrosclerosis, one case
each). The remaining 33 patients with pure TBMD were
selected as controls (the TBMD group); nine patients of the
TBMD group were included in our previous retrospective
study on microscopic hematuria.25 This study was approved
by the Clinical Research Ethics Committee of the Chinese
University of Hong Kong.
Determination of GBM thickness
All cases were processed according to standard methods for
electron microscopy, and examined on a CM100 Philips
microscope (EDAX, Eindhoven, Holland) as described
previously.26 Morphometry was carried out in a fixed setting,
from image on a monitor digitalized by the Leica Quantimet
500þ image analysis software (LEICA, Cambridge,
England), at the  4600 fixed magnification. The grid
intersect method was used, where 1-cm interval grid lines
image was overlapped with the capillary loop, and the
intersection of grid lines with the endothelial aspect of the
glomerular capillary basement membrane determined
the point of measurement. The linear intercept from that
point to the epithelial aspect provided a direct measure of the
basement membrane in nanometer. This measurement was
taken for all intersections between grid lines and a loop. For
each case, up to 18 loops from two glomeruli were assessed to
obtain a median thickness from at least 200 measurements.
The morphometry was calibrated using a commercial grid
with linear units, at the set magnification of  4600 and
fixing a pixel unit to 8.13 nm in length.
Immunofluorescence
Immunofluorescence study of a-3(IV) and a-5(IV) chains
were performed by the Wieslab Alport’s Syndrome Kit
(Wieslab AB, Ideon, Sweden) accordingly to manufacturer’s
instructions. Briefly, frozen specimens were prepared
for immunofluorescence on kidney biopsies and stored at
80 1C. Cryostat sections (5-mm thick) were incubated in the
primary antibodies against a-3(IV) and a-5(IV) at a working
dilution of 1:20 in 0.5% bovine serum albumin in phosphate-
buffered saline. As the secondary antibody, fluorescein
isothiocyanate-conjugated rabbit antibody against mouse
immunoglobulins was used at a working dilution of 1:20 in
phosphate-buffered saline/bovine serum albumin.
Clinical data
We excluded cases with segmental GBM thinning and
reviewed the clinical records of 74 patients. Baseline
demographic information and development of clinical events
were recorded. The time of onset was defined as the time of
the first detection of hematuria. Clinical events of this study
included: (i) detectable proteinuria (of at least trace by
urine albustix on two consecutive occasions); (ii) overt
proteinuria (of at least 1 g/day on two consecutive occasions);
(iii) development of hypertension (defined as systolic blood
pressures 4130 mm Hg, diastolic pressure 480 mm Hg, or
requirement of antihypertensive therapy); and (iv) impa-
ired renal function, which was defined as serum creati-
nine 4120 mmol/l or estimated glomerular filtration rate
o60 ml/min per 1.73 m2, as determined by the standard
MDRD formula.27
Statistics
Statistical analysis was performed by SPSS for Windows
software version 15.0 (SPSS, Chicago, IL, USA). Results were
expressed as mean±s.d. unless otherwise stated. Data were
compared by Student’s t-test, w2-test, or Fisher’s exact test as
appropriate. All probabilities were two tailed.
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Incidences of clinical events were estimated by Kaplan–
Meier method and compared by log-rank test. Multivariate
analysis with the Cox proportional hazard model was further
performed to look for independent predictors of clinical
events (as defined above). Loss of follow-up was a censored
observation for the analysis. Variables used for modeling were
sex, age at biopsy, body weight, presence of macroscopic
hematuria, GBM thickness, intraindividual variation of
GBM thickness (a marker of irregular GBM thinning),
baseline blood pressure, proteinuria, and estimated glomer-
ular filtration rate. Backward stepwise elimination was
applied to remove insignificant variables.
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